Key result
In patients with lung cancer, the development of venous thromboembolism was significantly associated with an increased risk of death (HR 1.80).
Why the study?
Risk factors and incidence of venous thromboembolism across lung cancer subtypes are not fully characterized, and routine thromboprophylaxis remains uncommon despite Khorana score recommendations.
Cohort (n=632)
No
Hazard Ratio: 1.8 (95% CI 1.2–2.75)
p-value: p=0.005
Venous thromboembolism is prevalent across all lung cancer subtypes and serves as an independent predictor of mortality, highlighting the need for improved risk stratification.
Further refines VTE risk by lung cancer subtype; leaves open whether subtype-specific prophylaxis improves outcomes.
Venous thromboembolism (VTE) is a frequent complication in patients with lung cancer, but the risk factors and incidence in different lung cancer subtypes have not been fully characterized. Despite multiple studies supporting the use of VTE prophylaxis in patients with cancer at increased risk of VTE by the Khorana score (KS), routine use of VTE prophylaxis is uncommon in clinical practice for these patients. This study further characterizes the risk factors and incidence of VTE and in patients with lung cancer at a university cancer center. Further, we assessed the association of KS and its individual components with overall survival in this same group of patients with lung cancer. Utilizing natural language processing and human review to detect thrombotic events in the electronic medical record, a 12-month incidence of 10.1% was identified in the 632 lung cancer patients analyzed. Significant risk factors included age <60 years and white blood cell count (WBC) ≥ 11× 10 9 /L, but KS itself was not significantly associated with VTE. The median overall survival was 12 months with VTE. The KS, age ≥ 60 years, stage III-IV, WBC ≥ 11× 10 9 /L, Hgb <10 gm/dL, BMI, surgery and VTE were identified as significant predictors of death. These findings warrant further validation, as the KS and two of its individual components in this study of lung cancer were significantly associated with reduced overall survival.
No takes yet. Share an insight, caveat, or question.
Plate et al. (2025) conducted a cohort in Lung cancer (n=632). Venous thromboembolism (VTE) vs. No VTE was evaluated on Overall survival (HR 1.80, 95% CI 1.20-2.75, p=0.005). In patients with lung cancer, the development of venous thromboembolism was significantly associated with an increased risk of death (HR 1.80).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: